Opus Genetics, Inc. Cash Flow-to-Debt Ratio
Opus Genetics, Inc. cash flow-to-debt ratio. Opus Genetics, Inc. (IRD) has a Cash Flow-to-Debt Ratio of -0.11x as of June 2026, meaning its operating cash flow of $-11.95 Million could theoretically repay 0% of its total liabilities ($105.95 Million) in one year. Check IRD operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Opus Genetics, Inc. (2019–2025)
Cash flow-to-debt ratio of Opus Genetics, Inc. from 2019 to 2025. Historical debt coverage capacity for Opus Genetics, Inc. across 7 annual periods. Check Opus Genetics, Inc. (IRD) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Opus Genetics, Inc. Cash Flow-to-Debt Ratio by Year (2019–2025)
Opus Genetics, Inc. cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for Opus Genetics, Inc.. For the full cash flow conversion analysis, see IRD cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.01x | $-35.25 Million | $34.90 Million | ▼ -19.0% |
| 2024 | -0.85x | $-25.58 Million | $30.14 Million | ▼ -208.5% |
| 2023 | -0.28x | $-1.11 Million | $4.04 Million | ▼ -105.3% |
| 2022 | 5.20x | $14.31 Million | $2.75 Million | ▲ +203.5% |
| 2021 | -5.02x | $-19.37 Million | $3.85 Million | ▼ -2202.7% |
| 2020 | -0.22x | $-6.80 Million | $31.15 Million | ▲ +43.3% |
| 2019 | -0.38x | $-3.59 Million | $9.34 Million | — |